1.
Am J Psychiatry
; 154(11): 1626, 1997 Nov.
Article
in English
| MEDLINE
| ID: mdl-9356581
Subject(s)
Antipsychotic Agents/therapeutic use , Pirenzepine/analogs & derivatives , Schizophrenia/drug therapy , Adult , Basal Ganglia Diseases/chemically induced , Basal Ganglia Diseases/epidemiology , Benzodiazepines , Chronic Disease , Drug Administration Schedule , Humans , Male , Middle Aged , Olanzapine , Pirenzepine/administration & dosage , Pirenzepine/adverse effects , Pirenzepine/therapeutic use , Schizophrenic Psychology , Social Adjustment , Treatment Outcome
2.
Psychiatry Res
; 73(1-2): 109-13, 1997 Nov 14.
Article
in English
| MEDLINE
| ID: mdl-9463844
ABSTRACT
Neurotrophin-3 (NT-3) may have a potential role in the pathogenesis of schizophrenia, given evidence of abnormal neurodevelopment in schizophrenia, as well as a potential association of an NT-3 gene polymorphism with schizophrenia. Cerebrospinal fluid NT-3 protein was assayed using an enzyme-linked immunosorbent assay in five patients with schizophrenia and 49 patients with medical illness. None of the patients with schizophrenia had detectable levels of NT-3 (above 4.7 pg/ml). Eleven samples from 10 different patients with medical or neurological illness had detectable levels of NT-3, associated with surgery for hydrocephalus or central nervous system infection.